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An accurate accessible test for early infant diagnosis (EID) is crucial for identifying HIV-infected infants and linking them to
treatment. To improve EID services in Ukraine, dried blood spot (DBS) samples obtained from 237 HIV-exposed children (<18
months of age) in six regions in Ukraine in 2012 to 2013 were tested with the AmpliSens DNA-HIV-FRT assay, the Roche COBAS
AmpliPrep/COBAS TaqMan (CAP/CTM) HIV-1 Qual test, and the Abbott RealTime HIV-1 Qualitative assay. In comparison
with the paired whole-blood results generated from AmpliSens testing at the oblast HIV reference laboratories in Ukraine, the
sensitivity was 0.99 (95% confidence interval [CI], 0.95 to 1.00) for the AmpliSens and Roche CAP/CTMQual assays and 0.96
(95% CI, 0.90 to 0.98) for the Abbott Qualitative assay. The specificity was 1.00 (95% CI, 0.97 to 1.00) for the AmpliSens and Ab-
bott Qualitative assays and 0.99 (95% CI, 0.96 to 1.00) for the Roche CAP/CTMQual assay. McNemar analysis indicated that the
proportions of positive results for the tests were not significantly different (P> 0.05). Cohen’s kappa (0.97 to 0.99) indicated
almost perfect agreement among the three tests. These results indicated that the AmpliSens DBS and whole-blood tests per-
formed equally well and were comparable to the two commercially available EID tests. More importantly, the performance char-
acteristics of the AmpliSens DBS test meets theWorld Health Organization EID test requirements; implementing AmpliSens
DBS testing might improve EID services in resource-limited settings.
Ukraine experienced the most severe human immunodefi-ciency virus (HIV) epidemic in Europe before prevention
measures began to slow transmission (1–3). In 2013, approxi-
mately 210,000 persons were living with HIV, and the HIV prev-
alence was 0.8% among adults 15 to 49 years of age and women at
childbirth (1–3). HIV infections in Ukraine mainly are the result
of injection drug use (4). However, heterosexual HIV transmis-
sion in Ukraine is increasing (4). Because of women’s biological
and social vulnerability (e.g., women engaging in commercial sex
work to provide funds for drugs for their male partners), women
are more prone to infection (4, 5). Women now represent 45% of
all adults living with HIV in Ukraine, and the majority of those
women are of reproductive age (4, 5). In 2001, the Ukrainian
government implemented a national program for prevention of
mother-to-child transmission. Since then, the rate of mother-to-
child transmission has decreased from 21% to 3.7% (6), as of
2011. Although the numbers of HIV-infected pregnant women
have plateaued, approximately 4,000 HIV-exposed children are
born each year (1, 4).
In order for HIV-infected children to receive antiretroviral
treatment as early as possible, accurate accessible early infant di-
agnosis (EID) of HIV is crucial. The World Health Organization
(WHO) strongly recommends using virological tests for EID, be-
cause infants and children of HIV-positive mothers acquire anti-
bodies transplacentally and the antibodies can persist in the in-
fants for up to 18 months after birth (7). Ukraine has had
insufficient capacity for full coverage with EID virological meth-
ods. Since 2006, Ukrainian laboratories have been using a DNA-
based PCR test, the AmpliSens DNA-HIV-FRT PCR assay (Inter-
LabService,Moscow, Russia), for EID using infants’ venous whole
blood (8). Using venous whole blood for EID presents challenges
in resource-limited settings and remote areas, because whole-
blood samples require cold-chain transportation and the condi-
tions for sample storage and processing are more stringent. Dried
blood spot (DBS) samples offer multiple advantages for EID, be-
cause the samples can be collected easily by heel prick or finger
stick and can be stored at ambient temperature for long periods
(9–15). Because of their greater stability at ambient temperature,
DBS samples can be transported by postal mail to centralized lab-
oratories for testing and, if packaged correctly, do not raise bio-
safety concerns regarding the health of postal workers (9–15).
Published data indicate that DBS samples are suitable and practi-
cal for quality EID and have aided service expansion in sub-Saha-
ran Africa (16–21). In our study, for the first time, the perfor-
mances of the AmpliSens DNA PCR assay and two commercially
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available and widely used DBS EID tests, i.e., the Roche COBAS
AmpliPrep/COBAS TaqMan (CAP/CTM)Qual test (Roche Diag-
nostics, Indianapolis, IN, USA) and the Abbott RealTime HIV-1
Qualitative test (Abbott Laboratories, Abbott Park, IL, USA) (22–
27), were evaluated by using DBS samples from HIV-exposed in-
fants in Ukraine and were compared with the performance of the
EID test in Ukraine, the AmpliSens whole-blood test.
MATERIALS AND METHODS
Samples and testing. From February 2012 to April 2013, DBS samples
were derived from venous blood collected in EDTA-containing tubes,
which was left over from testing of HIV-exposed infants18 months of
age at six oblast (equal to state or province) AIDS centers. In Ukraine,
infant HIV status is determined by two PCR results using the AmpliSens
whole-blood test. All specimens routinely collected for EID testing were
eligible for inclusion in this study. The residual blood was transported to
the Ukraine National AIDS Center for DBS preparation. The blood was
shipped under cold conditions, 24 h after collection. During the study
period, more than 2,600 infants born to HIV-infected mothers, from six
oblast AIDS centers inUkraine, were tested. Among the infants, 100 tested
positive for HIV. Along with the 100 HIV-positive samples, 137 HIV-
negative samples were randomly selected from the six oblast AIDS centers
and were included in the study. Among the 237 samples, 29 were from the
Crimean oblast, 41 from the Dnipropetrovsk oblast, 54 from the Donetsk
oblast, 35 from theMykolaiv oblast, 35 from the Kiev oblast, and 43 from
the Odessa oblast. At the National AIDS Center, the DBS samples were
prepared by spotting 70l of whole blood ontoWhatman 903 filter paper
for each spot, by using a measuring pipette. For each patient, two DBS
cards were obtained, with each card containing 5 DBSs. The DBS cards
were dried overnight at room temperature and then covered with folded
leaflets. The DBS cards were then packed in low-gas-permeable plastic
bags with desiccants and were stored at20°C until they were ready to be
shipped to the Centers for Disease Control and Prevention (CDC) (At-
lanta, GA, USA) for testing. All DBS samples were tested blindly with the
AmpliSens, Roche CAP/CTM Qual, and Abbott Qualitative assays.
DIA-DNA-HIV-FRT whole-blood DNA extraction protocol. The
DIA-DNA-HIV-FRTwhole-bloodDNA extraction procedure (DiaProph
Med, Kiev, Ukraine) includes three steps, i.e., (i) hemolysis and leukocyte
pelleting, (ii) nucleic acid (NA) extraction, and (iii) NA washing and
pelleting. In the first step, 250l of EDTA-treated whole blood from each
patient was hemolyzed twice. First a 6-min hemolysis procedure was con-
ducted in 1 ml of hemolytic solution, followed by centrifugation (Biofuge
Stratos Heraeus, Kendro, Germany) at 8,000 rpm for 2 min to obtain the
leukocyte pellet, and then a 3-min hemolysis procedure was conducted in
0.5 ml of hemolytic solution, followed by centrifugation at 8,000 rpm for
2 min to obtain the leukocyte pellet. In the second step, the leukocyte
pellet was incubated with 300 l of lysis solution and 25 l of universal
sorbent solution at room temperature for 10 min, to lyse the leukocytes
and to precipitate the NA. In this step, the extraction controls, i.e., a
negative control (5l of Tris-EDTA [TE] buffer) and a positive control (5
l ofHIV-positiveDNA) providedwith the kit, were processed alongwith
the patients’ samples to monitor the NA extraction process. After centrif-
ugation of the lysed leukocytes at 5,000 rpm for 30 s, the NA pellets were
obtained by removing the supernatant from each sample tube. In the third
step, the NA pellets were first washed with 300 l of washing solution 1,
followed by centrifugation at 5,000 rpm for 30 s. After centrifugation, the
supernatant was removed, and the NA pellets were washed again with 500
l of washing solution 2, followed by centrifugation at 10,000 rpm for 30
s. At the end of the centrifugation, the supernatant was removed from
each tube, and the NA pellet was dried at 65°C for 10 min. The dried NA
pellet was then dissolved in 50l of TE buffer, followed by centrifugation
at 12,000 rpm for 1 min. The purified NA solution was then ready for
DNA amplification or was stored at70°C until testing.
AmpliSens DBS DNA extraction protocol. The DBS samples were
processed by following the instruction manual (Federal Budget Institute
of Science, Central Research Institute for Epidemiology,Moscow, Russia)
instruction manual (28). One 12-mm DBS was processed per patient, to
compare the same amount of DNA input as with the Roche CAP/CTM
Qual and Abbott Qualitative EID tests. The AmpliSens DBS DNA extrac-
tion procedure included the lysis, NA extraction and pelleting, and NA
pellet washing steps. At the end of the procedure, 50 l of DNA was
obtained from each patient sample.
AmpliSens DNA amplification and result interpretation. The Am-
pliSens DNA amplification was performed by using two real-time PCR
instruments, i.e., the Rotor-Gene 6000 (Qiagen, Germantown,MD,USA)
and Agilent-StratageneMx3000P (Agilent Technologies, Santa Clara, CA,
USA) systems, both of which had been validated and recommended for
the AmpliSens test kit (29). The Rotor-Gene 6000 system was used at the
oblast AIDS centers in Ukraine for amplification of whole-blood samples,
and the Agilent-Stratagene Mx3000P system was used at the CDC for
amplification of DBS samples. The real-time PCR results were interpreted
by following the result interpretation matrix provided in the kit (28).
Briefly, when the extraction and amplification controlsmeet the criteria in
the matrix, any sample with a cycle threshold (CT) value of 40 for the
target and a positive result for the internal control (IC) is considered to
demonstrate a positive result. A negative result would have noCT value for
the target but a positive result for the IC.
Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Qual test. The
Roche CAP/CTMQual test was performed by following the manufactur-
er’s instructions (30).
Abbott RealTime HIV-1 Qualitative assay. The Abbott Qualitative
assay was performed by following the manufacturer’s instructions (31)
except for the specimen input volume; instead of two 12-mm DBSs, one
12-mm DBS was processed per patient. We chose to compare the same
input volume of whole blood (DNA) as for the Roche CAP/CTM Qual
and AmpliSens tests.
Statistical analysis. The sensitivity and specificity of each DBS test
were calculated by using the AmpliSens whole-blood test as the reference
group. The Wilson score method was used to calculate 95% confidence
intervals (CIs) for binomial proportions. The McNemar test was used to
assess whether the proportions of positive results for each DBS test dif-
fered from each other. If the P value was 0.05, then the proportions of
positive results for the DBS tests did not differ significantly from each
other. Cohen’s kappa was used to assess the agreement between the Am-
pliSenswhole-blood test and theDBS tests inHIVdiagnosis. Kappa values
of 0.81 to 1.0 indicated almost perfect agreement. All statistical analyses
were performed by using SAS software (version 9.3; SAS Institute, Inc.,
Cary, NC, USA).
Ethics review. The study was reviewed and approved by the State
Service of Ukraine on HIV/AIDS and Other Socially Dangerous Diseases.
DBS samples were delinked from identifying patient information before
being sent to the CDC for testing. The anonymous testing at the CDCwas
determined to be nonhuman subjects research by the Associate Director
for Science at the Center for Global Health, CDC (Atlanta, GA, USA).
RESULTS
Patient ages. The median age of the 237 children was 5 months.
Among the 237 children, 9% (21/237 patients) were3months of
age, 82% (195/237 patients) were 3 to12months of age, and 9%
(21/237 patients) were 12 to18 months of age.
Performance of AmpliSens DBS test versus AmpliSens
whole-blood test.A total of 237DBS samples, including 100HIV-
1-positive samples and 137 HIV-1-negative samples, were tested
with the AmpliSens assay (Table 1). Two HIV-negative DBS sam-
ples demonstrated noDNA results because their endogenous con-
trols (-globin) were not detected by the AmpliSens test. These
two samples were excluded from the data analysis for specificity.
Results indicated that AmpliSens testing usingDBS samples could
detect all of the positive samples that were detected by AmpliSens
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testing using whole-blood samples, except for one sample that
tested positive by whole-blood testing but negative by DBS testing
(Table 1). For the 135 samples that tested negative with the Am-
pliSens whole-blood test, the DBS test results matched exactly
(Table 1). The sensitivity and specificity of theAmpliSensDBS test
were 0.99 (95% CI, 0.95 to 1.00) and 1.00 (95% CI, 0.97 to 1.00),
respectively. The McNemar P value for the AmpliSens DBS test
was 1.0, indicating that the proportion of positive results obtained
with the AmpliSens DBS test was not significantly different from
the proportion obtained with the AmpliSens whole-blood test.
The Cohen’s kappa value for the AmpliSens DBS test was 0.99,
indicating almost perfect agreement between the AmpliSens DBS
test and the AmpliSens whole-blood test (Table 1).
Performance of Abbott Qualitative and Roche CAP/CTM
Qual DBS tests versus AmpliSens whole-blood test. A total of
237DBS sampleswere testedwith both theAbbottQualitative and
Roche CAP/CTM Qual tests. Among the 100 whole-blood sam-
ples that tested positive with the AmpliSens test, four of the paired
DBS samples were not detected by the Abbott Qualitative test
(Table 1). For all 137 whole-blood samples that tested negative
with the AmpliSens blood test, the Abbott Qualitative assay
yielded the same results with DBS samples (Table 1). Compared
with the AmpliSens whole-blood test, the sensitivity and specific-
ity of the Abbott Qualitative test were 0.96 (95% CI, 0.90 to 0.98)
and 1.00 (95% CI, 0.97 to 1.00), respectively (Table 1). The
McNemar P value for the Abbott Qualitative test was 0.13, indi-
cating that the proportion of positive results obtained with the
Abbott Qualitative assay was not significantly different from that
obtained with the AmpliSens whole-blood test. The Cohen’s
kappa value for the Abbott Qualitative assay was 0.97, indicating
almost perfect agreement between the Abbott Qualitative assay
and the AmpliSens whole-blood test (Table 1).
The Roche CAP/CTM Qual test results indicated that, among
the 100 whole-blood samples that tested positive with the Am-
pliSens test, one of the pairedDBS samples was not detected by the
Roche CAP/CTM Qual assay (Table 1). For all 137 whole-blood
samples that tested negative with the AmpliSens assay, the Roche
CAP/CTM Qual assay demonstrated the same results with DBS
samples, except for one DBS sample with a weak positive result
(Table 1). Compared with the AmpliSens whole-blood test, the
sensitivity and specificity of the Roche CAP/CTMQual assay were
0.99 (95%CI, 0.95 to 1.00) and 0.99 (95%CI, 0.96 to 1.00) (Table
1), respectively. The McNemar P value for the Roche CAP/CTM
Qual assay was 1.0, indicating that the proportion of positive re-
sults obtained with the Roche CAP/CTM Qual assay was not sig-
nificantly different from that obtained with the AmpliSens whole-
blood test. The Cohen’s kappa value for the Roche CAP/CTM
Qual assay was 0.98, indicating almost perfect agreement between
the Roche CAP/CTMQual assay and the AmpliSens whole-blood
test (Table 1).
Discordant results betweenDBS tests andAmpliSenswhole-
blood test. Among the three DBS tests, six DBS samples yielded
discordant results, compared with the results from the Am-
pliSens assay using whole blood (Table 2). Human errors and
potential cross-contamination were ruled out for the six dis-
cordant samples by repeating the tests with another DBS sam-
ple from the same patient. The HIV status of the six discordant
samples was confirmed at the Ukraine oblast AIDS centers. The
negative result fromAmpliSens whole-blood testing among the
six discordant results was confirmed with an HIV enzyme-
linked immunosorbent assay (ELISA), and the five positive re-
sults fromAmpliSens whole-blood testing were confirmed with
an HIV load test (Table 2). The results presented in Table 2
demonstrate that the discordant results were not age or oblast
specific. The availableCT values from the AmpliSens and Roche
CAP/CTM Qual DBS tests were considered high and indicated
weak positive results.







Total no. Sensitivity (95% CI) Specificity (95% CI) McNemar P KappaPositive Negative
Abbottb 0.96 (0.90–0.98) 1 (0.97–1.00) 0.13 0.97
Positive 96 0 96
Negative 4 137 141
Total 100 137 237
AmpliSensc 0.99 (0.95–1.00) 1 (0.97–1.00) 1 0.99
Positive 99 0 99
Negative 1 135d 136
Total 100 135 235
Rochee 0.99 (0.95–1.00) 0.99 (0.96–1.00) 1 0.98
Positive 99 1 100
Negative 1 136 137
Total 100 137 237
a DBS, dried blood spot; CI, confidence interval.
b Abbott Laboratories (Abbott Molecular, Inc., Des Plaines, IL, USA).
c Federal Budget Institute of Science, Central Research Institute for Epidemiology (Moscow, Russia).
d Two DBS samples with no DNA results were excluded.
e Roche Molecular Systems, Inc. (Branchburg, NJ, USA).
AmpliSens Testing Using DBS Samples for HIV Diagnosis
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DISCUSSION
DBS samples serve as suitable practical samples for quality EID in
multiple countries (16–21). To help Ukraine expand its EID ser-
vices and to increase infants’ and children’s access to EID in re-
source-limited settings or remote areas, the performance of
Ukraine’s EID test, i.e., the AmpliSens assay, as well as the Roche
CAP/CTM Qual and Abbott Qualitative assays, was evaluated by
using DBS samples from HIV-exposed Ukrainian infants or chil-
dren; those results were comparedwith the performance ofUkrai-
nian EID testing using venous whole-blood samples.
The results of our study demonstrated that the performance of
the AmpliSens assay using DBS samples was as good as that of the
AmpliSens assay using whole-blood samples and was comparable
to the performance of the Roche CAP/CTM Qual and Abbott
Qualitative EID tests. The sensitivity of 0.99 (95%CI, 0.95 to 1.00)
and the specificity of 1.00 (95%CI, 0.97 to 1.00) for the AmpliSens
DBS test exceeded the WHO 2010 recommendations for virolog-
ical tests, i.e., 0.95 for sensitivity and 0.98 for specificity at dif-
ferent HIV prevalence levels (7).
The AmpliSens DBS test had one discordant result, compared
with the AmpliSens whole-blood test. This discordant sample
tested positive with the AmpliSens whole-blood test but negative
with the DBS test (Table 2). This particular sample tested positive
with the Roche CAP/CTM Qual assay but had a high CT value of
34, indicating a weak positive result. The Abbott Qualitative
assay also yielded a weak positive result for that sample, as deter-
mined by reviewing the amplification curve. However, the Abbott
software did not provide a specificCT value for the qualitative test.
The discrepant results between the AmpliSens DBS test and the
AmpliSens whole-blood test might be caused by different sample
input volumes. The AmpliSens whole-blood test required 250 l
of whole blood per test, whereas the AmpliSensDBS test used only
one DBS per test, containing only 70 l of blood. The Abbott
Qualitative and Roche CAP/CTM Qual assays also used one DBS
per test, with 70 l of blood, which might explain why the Abbott
Qualitative assay missed four samples and the Roche CAP/CTM
Qual assay missed one sample that tested positive with the Am-
pliSens whole-blood test (Table 2). Other factors (e.g., amplifica-
tion cycle numbers and targeted regions for the tests) also might
contribute to the discordant results among the three DBS tests.
The total amplification cycle numbers were 37 for the Abbott
Qualitative assay, 40 for the Roche CAP/CTMQual assay, and 42,
with 5 additional cycles of non-real-time PCR amplification, for
the AmpliSens whole-blood and DBS tests. The targeted regions
for the tests also were different. The Roche CAP/CTMQual assay
targets the gag region and the Abbott Qualitative assay targets the
pol region of the HIV-1 virus (30, 31). Which region the Am-
pliSens test targets is not known, because that information is not
provided in the package insert. The efficiency of NA extraction for
each test and the HIV subtypes of the samples also might contrib-
ute to the discordant results, as discussed for an EID test evalua-
tion study in Kenya (22). HIV subtype information was not avail-
able in this study, but the subtypes for clinical samples in Ukraine
are primarily subtypes A and B (32–34).
Although all three DBS tests missed detection of one or a few
positive samples detected by the AmpliSens whole-blood test, a
sample that tested negative with the AmpliSens whole-blood test
was detected by the Roche CAP/CTM Qual assay with a weak
positive result, with aCT value of 34 (Table 2). Because this sample
was confirmed as negative by an ELISAwith a follow-up sample in
Ukraine (Table 2), this weak positive result indicated a false-pos-
itive result from the Roche CAP/CTM Qual assay. The potential
false-positive results from the Roche CAP/CTM Qual assay were
reported and discussed in an evaluation byMaritz et al. (23) of the
Roche CAP/CTM Qual assay versus the Roche COBAS Amplicor
DNA test, version 1.5 (RocheMolecular Systems Inc., Pleasanton,
CA, USA), for EID. Maritz et al. (23) demonstrated that a false-
positive sample identified by the Roche CAP/CTM Qual assay
tended to have a flat amplification slope and a high CT value,
which together indicate a nonspecific signal. Our findings are con-
sistent with those of Maritz et al. (23). To rule out potential false-
positive results from the Roche CAP/CTM Qual assay, Maritz
et al. recommended that Roche CAP/CTM Qual assay users re-
view the CT value and fluorescence intensity of the amplification
curve for each sample, as reported by the AMPLILINK software
(Roche Molecular Systems Inc., Pleasanton, CA, USA) (23). If
Roche CAP/CTM Qual assay users observe a sample with an ab-
solute fluorescence intensity of 5 and a CT value of 32, then
they should request a follow-up sample from the patient and re-
peat the testing for confirmation (23).
The interpretation of the results of the AmpliSens test should
be noted. According to the AmpliSens kit instructions, when the








Qualitativeb AmpliSensc Roche CAP/CTMd
1 7 Crimean Negativee Negative Negative Positive, CT of34
2 5 Kiev Positivef Negative Positive, CT of 35 Positive, CT of34
3 3 Dnipropetrovsk Positivef Negative Positive, CT of35 Negative
4 14 Dnipropetrovsk Positivef Negative Positive, CT of 33 Positive, CT of34
5 4 Donetsk Positivef Positiveg Negative Positive, CT of34
6 6 Odessa Positivef Negative Positive, CT of 34 Positive, CT of34
a DBS, dried blood spot; CT, cycle threshold.
b Abbott Laboratories (Abbott Molecular, Inc., Des Plaines, IL, USA).
c Federal Budget Institute of Science, Central Research Institute for Epidemiology (Moscow, Russia).
d Roche Molecular Systems, Inc. (Branchburg, NJ, USA).
e Confirmed by an ELISA (Ani Labsystems Ltd., Finland) and the Genscreen Ultra HIV Ag-Ab test (Bio-Rad, France).
f Confirmed by the Abbott HIV Viral Load test.
g The CT value was not provided by the Abbott test software, but the amplification curve indicated a weak positive result.
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extraction and amplification controls meet the requirements in-
dicated in the package insert, any sample result with a CT value of
40 for the target and a positive signal for the IC should be con-
sidered an HIV-positive result. In our study, however, only a few
clinically positive DBS results had CT values of 35. Given our
experience regarding potential false-positive results with high CT
values, we recommend that, when a samplewith aCT value of 35 to
40 is observed, AmpliSens test users may consider requesting a
follow-up sample from the patient and repeating the test to con-
firm the patient’s HIV status.
The technical procedure for the AmpliSens assay is labor-in-
tensive and requires highly trained technicians, because it is chal-
lenging to work with a small NA pellet from each sample in a
multistep procedure. Additionally, close attention needs to be
paid during the sample processing and amplification set-up steps,
to avoid potential sample cross-contamination, with sample tubes
being opened multiple times and processed next to each other.
When a laboratory chooses to use the AmpliSens test for EID, the
laboratory should have comprehensive quality assurance and
quality control procedures in place, and those procedures should
be followed closely. The format of the AmpliSens test allows users
to process 96 samples per day. However, processing 96 samples in
a day whenworking with such a long procedure is challenging and
may be impractical for most laboratories. This test may be best
suited to a laboratory with low or medium EID sample input
(from a few to several dozen samples per week). If a laboratory
chooses to run a full 96-sample run for the amplification, then the
laboratory can combine extracted DNA samples from different
days or runs. However, this approach should be contingent on the
return of results to patients not being delayed.
In conclusion, our study demonstrates that the AmpliSens
DBS test performs as well as testingwithwhole-blood samples and
matches the expected outcomes of the two widely used commer-
cial EID tests. Furthermore, the AmpliSens assaymeets or exceeds
the WHO EID test qualification requirements, and using DBS
samples might improve EID services in resource-limited settings.
The findings in this study alsomay benefit countries that are using
the AmpliSens test with venous whole-blood samples for EID.
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